Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28739842 | 0.98 | ALDH1A1 (0.69) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Bromide SCHEMBL1449856 | 0.98 | TSHR (0.69) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Bromide SCHEMBL2854923 | 0.98 | TSHR (0.69) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Bromide SCHEMBL1006745 | 0.98 | TSHR (0.69) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Bromide SCHEMBL711677 | 0.98 | TSHR (0.69) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Bromide SCHEMBL5573865 | 0.98 | TSHR (0.69) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Bromide SCHEMBL8091612 | 0.98 | TSHR (0.69) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Bromide SCHEMBL3437057 | 0.98 | TSHR (0.69) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Bromide SCHEMBL20541362 | 0.98 | TSHR (0.69) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 | |
| Bromide SCHEMBL27033077 | 0.98 | TSHR (0.69) | ALDH1A1CYP1A2CYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1796 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713317-A1 | A PROCESS FOR PURIFICATION OF ETHOFUMESATE | Adama Agan Ltd. (IL) | 2026-03-25 | — | — | EP | claimed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| US-20250282817-A1 | COMPOUNDS FOR DELIVERING GLUTATHIONE TO A TARGET AND METHODS OF MAKING AND USING THE SAME | OREGON STATE UNIVERSITY (US) | 2025-09-11 | — | — | US | claimed |
| WO-2024236570-A1 | A PROCESS FOR PURIFICATION OF ETHOFUMESATE | ADAMA AGAN LTD. (IL) | 2024-11-21 | — | — | WO | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-118019801-A | Fluoropolymer compositions and methods of making the same | 阿科玛股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | QUADREL S.R.L. (IT) | 2023-11-16 | — | — | US | claimed |
| EP-3781544-B1 | PROCESS FOR THE PREPARATION OF ILOPROST | EUROAPI HUNGARY LLC (HU) | 2023-11-08 | — | — | EP | claimed |
| EP-3468563-B1 | COMPOUNDS FOR DELIVERING GLUTATHIONE TO A TARGET AND METHODS OF MAKING AND USING THE SAME | UNIV OREGON STATE (US) | 2023-09-13 | — | — | EP | claimed |
| EP-4216960-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | Quadrel S.r.l. (IT) | 2023-08-02 | — | — | EP | claimed |
| EP-0544899-B1 | Prostaglandins | PHARMACIA AB (SE) | 1995-09-06 | — | — | EP | claimed |
| EP-0373915-B1 | NOVEL THROMBOXANE A2 ANTAGONISTS | BTG INTERNATIONAL LIMITED (GB) | 1993-08-18 | — | — | EP | claimed |
| EP-0544899-A1 | Prostaglandins. | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1993-06-09 | — | — | EP | claimed |
| WO-1993000329-A1 | CHEMICAL PROCESS | KABI PHARMACIA AB (SE) | 1993-01-07 | — | — | WO | claimed |
| US-5055582-A | Process for preparing thromboxane A2 antagonists | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-10-08 | — | — | US | claimed |
| WO-1990006917-A1 | NOVEL THROMBOXANE A2 ANTAGONISTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-06-28 | — | — | WO | claimed |
| EP-0373915-A1 | Novel thromboxane A2 antagonists | BTG INTERNATIONAL LIMITED (GB) | 1990-06-20 | — | — | EP | claimed |
| EP-0043446-B1 | INTERMEDIATES OF 13-THIA-PROSTAGLANDIN, THEIR PREPARATION AND APPLICATION TO THE SYNTHESIS OF 13-THIA-PROSTAGLANDIN DERIVATIVES | MERCK PATENT GmbH (DE) | 1984-02-22 | — | — | EP | claimed |
| EP-0043446-A1 | Intermediates of 13-thia-prostaglandin, their preparation and application to the synthesis of 13-thia-prostaglandin derivatives | MERCK PATENT GmbH (DE) | 1982-01-13 | — | — | EP | claimed |
| US-3992439-A | ESTERIFICATION, ACYLATION, HYDROGENATION, OXIDATION, HYDROLYZING | PFIZER INC. (US) | 1976-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282817-A1 | COMPOUNDS FOR DELIVERING GLUTATHIONE TO A TARGET AND METHODS OF MAKING AND USING THE SAME | GSR, TXN2, GLS | ALDH1A1 691/4885CYP1A2 4193/4885CYP2D6 2833/4885 |
| US-20230365602-A1 | COMPOUND FOR USE IN THE TREATMENT OF PROTOZOAL DISEASES AND PROCESS FOR PRODUCTION OF SAID COMPOUND | PIGO, PIGS, AGPS | ALDH1A1 3563/4885CYP1A2 1194/4885CYP2D6 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.